We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.20 | 0.98% | 124.00 | 122.60 | 124.00 | 124.00 | 122.60 | 122.60 | 254,260 | 11:50:43 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.76 | 826.75M |
TIDMSYNC Syncona Limited Total Voting Rights 31 August 2018 Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 31 August 2018 the total number of ordinary shares in issue now stands at 661,222,309 and the total number of voting rights in the Company is 661,222,309 ordinary shares. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. [ENDS] Enquiries Syncona Ltd Annabel Clay Tel: +44 (0) 20 7611 2031 Northern Trust International Fund Administration Services (Guernsey) Limited Company Secretary Tel: 01481 745001 Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com About Syncona: Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need. END
(END) Dow Jones Newswires
August 31, 2018 11:08 ET (15:08 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions